Jialin Qian

Jialin Qian


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
HQHuiping Qiang
Huiping Qiang
YLYuqiong Lei
Yuqiong Lei
YSYinchen Shen
Yinchen Shen
JLJiaqi Li
Jiaqi Li
HZHua Zhong
Hua Zhong
TCtianqing Chu
tianqing Chu
Background: The incidence of bone metastases in non-small cell lung cancer (NSCLC) patients is about 30–40% and bone-related events can seriously affect quality of life. Immune checkpoint inhibitor (ICI) therapy has become the standard treatment for advanced NSCLC patients. However, the specific efficacy of ICIs in NSCLC patients with bone metastases remains unclear. The aim of the present study was to explore the prognosis of immunotherapy in this population and to find potential biomarkers. Methods: In this retrospective study, a total of 110 advanced NSCLC patients with bone metastases who received pembrolizumab therapy were enrolled. Patient characteristics; palliative bone radiotherapy or bone-targeted therapy; serum levels of lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR) at baseline were assessed. The correlation of these factors with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) was analyzed. Results: The ORR of the total population was 29.1%, and PFS and OS were 7.0 and 14.8 months, respectively. Fifty-eight patients (52.7%) received pembrolizumab treatment as first-line therapy, and 52 patients (47.3%) as second-line therapy or beyond [ORR: 41.4% vs. 15.4%, P=0.011; PFS: 9.0 vs. 4.0 months, P=0.004; OS: not reached (NR) vs. 11.5 months, P<0.0001]. Bone therapy, including palliative bone radiotherapy and bone-targeted therapy, increased the ORR (34.9% vs. 11.1%, P<0.0001) and prolonged PFS (8.5 vs. 2.0 months, P=0.002). Eastern Cooperative Oncology Group performance status score of 0–1 [OS: hazard ratio (HR) =0.117, P<0.0001] and first-line pembrolizumab therapy (OS: HR =0.372, P=0.004) were independent predictors of OS. Patients whose baseline serum LDH level was ≤240.5 IU/L (NR vs. 10.0 months, P<0.0001) or NLR ≤5.55 (NR vs. 18.0 months, P=0.039) showed longer OS. Conclusions: The efficacy of Pembrolizumab therapy is confirmed in advanced NSCLC patients with bone metastases, particularly when palliative bone radiotherapy or bone-targeted therapy is delivered. Baseline serum LDH level ≤240.5 IU/L and NLR ≤5.55 might predict the prognosis of patients with bone metastases from advanced NSCLC treated with immunotherapy.

1 February 2017 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YZYan Zhou
Yan Zhou
ZHZhangguo Hu
Zhangguo Hu
SCShuhui Cao
Shuhui Cao
BYBo Yan
Bo Yan
JQJialin Qian
Jialin Qian
HZHua Zhong
Hua Zhong
Lung cancer is the most common malignancy in humans. An increased population of CD4+Foxp3+ regulatory T cells (Tregs) in the tumor-associated microenvironment plays an important role in cancer immune evasion. The exact role and the involved mechanisms of concomitant H37Rv infection in non-small cell lung cancer (NSCLC) development are still not clear. Here, we showed that H37Rv infection promoted NSCLC cell growth with a higher percentage of Tregs found in draining lymph nodes. We also determined in vitro that H37Rv infection induced macrophage maturation and PD-L1 expression, which promoted Treg proportion, with enhanced proliferation suppression function. Mechanism analysis revealed that AKT-mTORC1 signal was important for PD-L1 expression induced by H37Rv infection. Suppressing of AKT-mTORC1 signal by rapamycin or raptor deficiency showed decreased PD-L1 levels which further reduced Treg proportion in a co-culture system. Finally, tumor-bearing mice injected with H37Rv plus rapamycin enhance the immune response of lung cancer compared with injected with H37Rv alone. This study demonstrated that concomitant H37Rv infection promote NSCLC tumor immune eacape through enhancing Treg proportion.

8 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HQHuiping Qiang
Huiping Qiang
JLJiaqi Li
Jiaqi Li
QCQing Chang
Qing Chang
YSYinchen Shen
Yinchen Shen
JQJialin Qian
Jialin Qian
TCtianqing Chu
tianqing Chu
Background: Chemotherapy is the main treatment for patients with lung squamous cell carcinoma (LUSC). However, how chemotherapy affects their immune system is rarely reported. This study was aimed to compare the differences in the immune microenvironment of LUSC patients with or without chemotherapy.Methods: A total of 494 LUSC samples were obtained from The Cancer Genome Atlas (TCGA) database. The immune cell infiltration was evaluated by the ssGSEA algorithm, and the tumor subtype was assayed by ConsensusClusterPlus. The differences in tumor mutation burden (TMB) and clinical information between the two types were then compared. Additionally, the differentially expressed genes (DEGs) between two types were analyzed and hub genes were validated in the GEO database.Results: LSCC samples in TCGA were divided into three subtypes. Then, combining the tumor subtype and immune scores, the samples were divided into hot and cold tumors. Regardless of whether LUSC patients received chemotherapy, the survival of the hot tumor group was not significantly prolonged compared with that of the cold tumor group. For LUSC patients who received chemotherapy, the TMB value in hot tumor group was significantly higher. Total 501 DEGs were identified between two groups. The high expressions of hub genes CD19, CTLA4, FCGR3B, CD80, IL-10, etc. were also validated in the GSE37745 dataset.Conclusion: Chemotherapy does not affect the survival and prognosis of LUSC patients, but it significantly increases the TMB value of patients with hot tumor. The DEGs, especially hub genes, such as CD19, CTLA4, and FCGR3B, may serve as biomarkers to distinguish cold and hot tumors in LUSC.

1 November 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
QCQing Chang
Qing Chang
JLJiaqi Li
Jiaqi Li
YZYan Zhu
Yan Zhu
HQHuiping Qiang
Huiping Qiang
HLHaijiao Lu
Haijiao Lu
TCtianqing Chu
tianqing Chu
Background: For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed to investigate the effect and safety of neoadjuvant immunotherapy for patients with resectable NSCLC including those with coexisting COPD and the effect on patients’ lung function. Methods: Data of patients with resectable NSCLC who received neoadjuvant immunotherapy at the Shanghai Chest Hospital were retrospectively analyzed. Results: A total of 57 patients were enrolled and 18 of those were with coexisting COPD. For COPD patients, the objective response rate (ORR), major pathological response (MPR), and pathological complete response (pCR) were 44.4%, 55.6%, and 38.9%, respectively, which were not statistically different from those of non-COPD patients. The 2-year event-free survival (EFS) and overall survival (OS) rates were 73.7% and 88.5%, respectively, which were lower than those of patients without COPD, but the difference was not statistically significant. After neoadjuvant immunotherapy, the ratio of forced expiratory volume in 1 second (FEV1), the ratio of FEV1 to the predicted value (FEV1%pred), forced vital capacity (FVC), and the ratio of FVC to the predicted value (FVC%pred) all improved, however, carbon monoxide diffusing capacity (DLCO) and DLCO adjusted by hemoglobin (DLCOc) were lower. For patients with COPD, only FEV1 improved after immunotherapy. Conclusions: For resectable NSCLC patients with COPD, neoadjuvant immunotherapy could achieve better pathological response, survival benefit and improve patients’ lung function.

22 March 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
QCQing Chang
Qing Chang
YZYanwei Zhang
Yanwei Zhang
JXJianlin Xu
Jianlin Xu
RZRunbo Zhong
Runbo Zhong
HQHuiping Qiang
Huiping Qiang
TCtianqing Chu
tianqing Chu
Background: The study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab (PemPBev) and paclitaxel/carboplatin/bevacizumab (PacCBev) as first‐line therapy for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC) patients with wild‐type driver genes in a real‐world setting.Methods: We retrospectively collected the medical records of advanced NS‐NSCLC patients with wild‐type driver genes administered first‐line PemPBev or PacCBev therapy at Shanghai Chest Hospital between January 2014 and June 2016, and analyzed the differences in survival outcomes, efficacy, and safety between PemPBev and PacCBev treatment.Results: A total of 390 patients were included in our analysis: 249 in the PemPBev group and 141 in the PacCBev group. Patients administered PemPBev experienced significantly improved progression‐free survival (PFS) and overall survival (OS) compared to those administered PacCBev (PFS 7.5 vs. 6.2 months, hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.53–0.84, P < 0.001; OS:18.6 vs. 16.0 months, HR 0.68, 95% CI 0.52–0.90, P = 0.002). The objective response rate (ORR) and disease control rate (DCR) were similar between the groups (ORR 21.7% vs. 30.5%, P = 0.053; DCR 69.1% vs. 67.4%, P = 0.728). There was no significant difference in the incidence of adverse events between the groups (64.7% vs. 68.8%; P = 0.407), but the incidence of peripheral neuropathy in the PacCBev group was higher than in the PemPBev group (7.8% vs. 2.4%; P = 0.012).Conclusion: Our study shows that for advanced NS‐NSCLC patients with wild‐type driver genes, first‐line PemPBev might be a better treatment option compared to PacCBev.

1 August 2026 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
KHKuofang Huang
Kuofang Huang
SPShifei Pan
Shifei Pan
HDHuishu Dong
Huishu Dong
HLHaijiao Lu
Haijiao Lu
BYBo Yan
Bo Yan
TCtianqing Chu
tianqing Chu
Background: Direct real-world comparisons of pembrolizumab plus chemotherapy and bevacizumab plus chemotherapy in programmed cell death ligand 1 (PD-L1)-negative advanced non-squamous non-small cell lung cancer (NSCLC) are limited. We compared response, survival, safety, and blood biomarkers between these regimens. Methods: This single-center retrospective cohort included 160 patients treated at Shanghai Chest Hospital from May 2017 to October 2023: 76 received pembrolizumab plus platinum-pemetrexed chemotherapy and 84 received bevacizumab plus the same chemotherapy backbone. Eligibility required advanced non-squamous NSCLC, PD-L1 tumor proportion score <1%, no actionable driver alteration, Eastern Cooperative Oncology Group performance status 0–1, at least two treatment cycles, and complete data. Laboratory time points were defined as T0 (within 1 week before treatment) and T2 (after two treatment cycles); objective response rate (ORR) and disease control rate (DCR) were assessed after two treatment cycles. Cutoffs were selected using X-tile. Treatment-group Cox models adjusted for age, sex, smoking, stage, metastatic sites, baseline lactate dehydrogenase (LDH), and prognostic nutritional index (PNI); regimen-specific models included variables with univariable P<0.10. Results: The pembrolizumab cohort was older and included more men and patients with lung metastases. At the two-cycle response assessment, ORR (35.5% vs. 33.3%, P=0.77) and DCR (92.1% vs. 90.5%, P=0.72) did not differ significantly; median progression-free survival was also not significantly different [PFS; 8.8 vs. 9.9 months; adjusted hazard ratio (HR) 1.15, 95% confidence interval (CI): 0.80–1.68; P=0.45]. Median overall survival (OS) was 23.2 versus 20.8 months, in the pembrolizumab group and the bevacizumab group, respectively (P=0.04); adjusted mortality was lower with pembrolizumab plus chemotherapy (HR 0.58, 95% CI: 0.39–0.88; P=0.01). Documented grade ≥3 treatment-related adverse events occurred in 34.2% versus 44.0% in the pembrolizumab group and the bevacizumab group, respectively (P=0.20). In the pembrolizumab cohort, higher baseline LDH (>155 U/L) and ΔLDH (>501 U/L) were independently associated with shorter PFS, whereas higher PNI at T2 (>41.5) was associated with longer PFS; higher PNI at T0 (>47) and T2 (>39.5) were independently associated with longer OS. In the bevacizumab cohort, higher baseline LDH (>255 U/L for PFS; >250 U/L for OS) was independently associated with worse outcomes, whereas higher PNI at T2 (>47) was associated with longer PFS and higher PNI at T0 (>48) and T2 (>44) were associated with longer OS. Conclusions: In this retrospective non-randomized cohort, pembrolizumab plus chemotherapy and bevacizumab plus chemotherapy showed no statistically significant differences in response or PFS, whereas pembrolizumab plus chemotherapy was associated with longer adjusted OS. LDH and PNI provided complementary prognostic information, particularly early on-treatment PNI, supporting further evaluation of these routinely available markers for dynamic risk assessment. Prospective multicenter studies are needed to confirm the treatment association and biomarker thresholds.